CARLSBAD, Calif., July 1 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' business update
When: Tuesday, July 1, 2008, at 10:00 a.m. ET / 7:00 a.m. PT
Via internet: Simply log onto our web site http://www.isispharm.com and click on the webcast icon on our home page.
Via telephone: In the United States, call 1-877-548-7901 five to ten
minutes prior to the call. You will be asked to provide your name and
indicate that you wish to participate in Isis Pharmaceuticals' conference
call hosted by Dr. Stanley Crooke.
Contacts: Kristina Lemonidis
Associate Director, Investor Relations
Amy Blackley, Ph.D.
Manager, Corporate Communications
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 18
drugs in development. Isis' drug development programs are focused on
treating cardiovascular and metabolic diseases. Isis' partners are
developing antisense drugs invented by Isis to treat a wide variety of
diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is
developing and commercializing the Ibis T5000(TM) Biosensor System, a
revolutionary system to identify infectious organisms. Isis is a joint
owner of Regulus Therapeutics LLC, a joint venture focused on the
discovery, development and commercializat
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved